Hikma Pharmaceuticals Plc · LSE:HIK
Hikma Pharmaceuticals — 42nd Annual J.P. Morgan Healthcare Conference 2024
10 slides from Hikma Pharmaceuticals's conference presentation, January 2024
Slide 1: Better health. Within reach. Every day.
Better health. Within reach. Every day. Hikma Pharmaceuticals J.P. Morgan Healthcare Conference January 2024
Slide 2: Our diversified global business
Our diversified global business Leading market positions Positioned for growth Amongst the leading companies Refreshed strategy focused on harnessing across our geographies opportunities across all three businesses Operational and quality excellence Broad portfolios No significant product concentrat
Slide 3: Our track record of growth and healthy cash generation
Our track record of growth and healthy cash generation Core revenue Core EBITDA Operating cash flow (millions) (millions) (millions) +5% CAGR +6% CAGR $638 $727 $2,553 $2,517 $674 $694 $2,341 $530 $2,203 $593 $472 $464 $2,076 $549 $430 26% 27% 29% 28% 28% 2018 2019 2020 2021 2022 2018 2019 2020 2021
Slide 4: Our strategy for growth
Our strategy for growth operational efficiencies and embrace new technologies, maintaining our high-quality levels our broad portfolio and strong commercial capabilities a more differentiated pipeline into adjacent businesses and geographies our people and cultivate a unified culture responsibly acr
Slide 5: Three high quality businesses
Three high quality businesses • >$1.1 bn revenue (2022), 9% 10-year CAGR and core operating margin mid-30s and above • Top 3 generic injectable manufacturer in the US 41% of H1 2023 Revenue by volume2 49% of H1 2023 Core operating profit1 • Broad portfolio of over 150 products in the US and growing
Slide 6: Injectables: Our strategy in action
Injectables Our strategy in action Projects in 75 US Injectables 1 • Grow our sterile compounding business • Enhance internal technical know-how to (503B) in the US Conventional increase pipeline complexity • Increase focus on leveraging spare • Develop more ready-to-use products to capacity for con
Slide 7: Branded: Our strategy in action
Branded Our strategy in action 130 Products in Branded 1 • Focus on being there for our customers across the healthcare • Targeting >60% of sales from chronic CNS Other medicines by 2028 ecosystem • Focus on introducing first to market and • Educate HCPs, pharmacists, payers 12% 12% Anti- infectives
Slide 8: Generics: Our strategy in action
Generics Our strategy in action 49 Programmes in Generics 1 • Add more complex generics within our • Grow and defend our in-line portfolio, ER Oral Solid Nasal core expertise (e.g. nasal sprays and ensuring we can respond quickly to market inhalation) disruptions 12% 12% • Invest in new launches for
Slide 9: A strong investment case
A strong investment case A solid platform for Increasingly Strong balance sheet and A clear, profitable growth across diverse portfolio a track record of delivering refreshed strategy all three businesses and pipeline value for shareholders for growth Underpinned by our commitment to act responsibly
Slide 10: Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC 10
Hikma Pharmaceuticals — 42nd Annual J.P. Morgan Healthcare Conference 2024 on 6ix